<h1>Akums Drugs sees 12% EBITDA and 15% PAT growth in Q3 FY25, driven by CDMO success and new contracts.</h1> Akums Drugs and Pharmaceuticals Ltd. reported a strong financial performance for Q3 FY25, with a 12% year-on-year increase in Adjusted EBITDA and a 15% rise in Adjusted PAT. Despite a 6.1% decline in total income YoY, the company achieved an EBITDA of Rs 1,359 million and a PAT of Rs 663 million. The core CDMO segment drove profitability, while API losses decreased. The company secured a EUR200 million contract to supply products to European markets, aiming to expand its global CDMO presence. Additionally, Akums in-licensed new products in dermatology and metabolic segments to boost future growth.